- Ihre Herausforderungen
- Unsere Lösung
- Neuigkeiten und Veranstaltungen
- Wissensportal
- Über uns
- Diagnostics
Im Jahr 2007 zeigte eine Biopsie, dass Donna Gaidamak an Lungenkrebs des Stadiums 4 litt, der in das Gehirn metastasiert hatte. Donna wurde mit dem Vysis ALK Break Apart FISH-Sonden-Kit von Abbott auf eine Rekombination des ALK-Gens getestet. Die Ergebnisse bewiesen, dass sie ALK-positiv war, und sie wurde sofort auf XALKORI® (Crizotinib) eingestellt. Heute kann Donna wieder das tun, was sie liebt: Radfahren, Skifahren, Kajakfahren und Segeln.
Anwendungsgebiet
Das Vysis ALK Break Apart FISH-Sonden-Kit dient zum Nachweis von Rekombinationen mit Beteiligung des ALK-Gens über Fluoreszenz-in-situ-Hybridisierung (FISH) in formalinfixierten, paraffineingebetteten (FFPE) Gewebeproben von nicht-kleinzelligem Lungenkrebs (NSCLC).
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.